Literature DB >> 21718387

Development of membrane type-1 matrix metalloproteinase-specific activatable fluorescent probe for malignant tumor detection.

Yoichi Shimizu1, Takashi Temma, Kohei Sano, Masahiro Ono, Hideo Saji.   

Abstract

Membrane type-1 matrix metalloproteinase (MT1-MMP) is a protease that activates pro-MMP-2 and pro-MMP13, which are related to tumor malignancy. Therefore, probes that specifically image MT1-MMP would be useful for malignant tumor diagnosis. In the present study, we prepared rhodamine X-conjugated anti-MT1- MMP antibody (anti-MT1-MMP mAb-ROX) as an activatable fluorescent probe and evaluated its usefulness for MT1-MMP-specific imaging. Anti-MT1-MMP mAb-ROX was obtained in a quenched form with approximately three ROX molecules per mAb. Its fluorescence intensity increased approximately 14-fold in the presence of detergent, which is suitable for activatable systems. C6 glioma cells and MCF-7 human breast adenocarcinoma cells were used as MT1-MMP-positive and MT1-MMP-negative models, respectively. The fluorescence intensity of C6 cells treated with anti-MT1-MMP mAb-ROX, but not ROX-conjugated isotype control antibody (NC Ab-ROX), increased with time and was significantly higher than that of MCF-7 cells at 6 h (P < 0.001). The fluorescence intensity of cells treated with anti-MT1-MMP mAb-ROX was also suppressed by pre-treatment with a MT1-MMP endocytosis inhibitor (P < 0.05). Furthermore, the probes were intravenously administered to C6 and MCF-7 xenografted mice. The tumor-to-muscle (T/M) ratio of the anti-MT1-MMP mAb-ROX group was 15.1 ± 3.2 at 48 h and was significantly higher than that of the NC Ab-ROX group (T/M ratio = 4.6 ± 3.0, P < 0.05) in C6 xenografted mice, while the T/M ratio of the anti-MT1-MMP mAb-ROX and NC Ab-ROX groups was not different in MCF-7 xenografted mice. These findings suggest that anti-MT1-MMP mAb-ROX is a promising probe for specifically detecting MT1-MMP-expressing tumors.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21718387     DOI: 10.1111/j.1349-7006.2011.02020.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  6 in total

Review 1.  Chemical biology for understanding matrix metalloproteinase function.

Authors:  Anna Knapinska; Gregg B Fields
Journal:  Chembiochem       Date:  2012-08-30       Impact factor: 3.164

2.  In vivo imaging of membrane type-1 matrix metalloproteinase with a novel activatable near-infrared fluorescence probe.

Authors:  Yoichi Shimizu; Takashi Temma; Isao Hara; Akira Makino; Naoya Kondo; Ei-Ichi Ozeki; Masahiro Ono; Hideo Saji
Journal:  Cancer Sci       Date:  2014-07-31       Impact factor: 6.716

Review 3.  Selecting Targets for Tumor Imaging: An Overview of Cancer-Associated Membrane Proteins.

Authors:  Martin C Boonstra; Susanna W L de Geus; Hendrica A J M Prevoo; Lukas J A C Hawinkels; Cornelis J H van de Velde; Peter J K Kuppen; Alexander L Vahrmeijer; Cornelis F M Sier
Journal:  Biomark Cancer       Date:  2016-09-27

4.  Monitoring and Inhibiting MT1-MMP during Cancer Initiation and Progression.

Authors:  Sonia Pahwa; Maciej J Stawikowski; Gregg B Fields
Journal:  Cancers (Basel)       Date:  2014-02-17       Impact factor: 6.639

5.  Investigation of a MMP-2 activity-dependent anchoring probe for nuclear imaging of cancer.

Authors:  Takashi Temma; Hirofumi Hanaoka; Aki Yonezawa; Naoya Kondo; Kohei Sano; Takeharu Sakamoto; Motoharu Seiki; Masahiro Ono; Hideo Saji
Journal:  PLoS One       Date:  2014-07-10       Impact factor: 3.240

6.  Targeting MT1-MMP as an ImmunoPET-Based Strategy for Imaging Gliomas.

Authors:  A G de Lucas; A J Schuhmacher; M Oteo; E Romero; J A Cámara; A de Martino; A G Arroyo; M Á Morcillo; M Squatrito; J L Martinez-Torrecuadrada; F Mulero
Journal:  PLoS One       Date:  2016-07-27       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.